Cons: After lung stereotactic ablative radiotherapy for a peripheral stage I non-small cell lung carcinoma, radiological suspicion of a local recurrence is not sufficient indication to proceed to salvage therapy

Meredith Giuliani, Andrea Bezjak


Stereotactic body radiotherapy (SBRT) or stereotactic ablative radiotherapy (SABR) has become the standard of care for inoperable stage I non-small cell lung carcinoma (NSCLC). SBRT for peripheral tumors is well tolerated with minimal side effects (1,2) and results in excellent local control (2). While local recurrence is uncommon following lung SBRT, with the increasing use of SBRT in operable patients, there is a greater need to identify and manage local recurrences.